Could a One-Two drug punch beat tough colon cancer?
NCT ID NCT03519412
First seen Mar 16, 2026 · Last updated May 07, 2026 · Updated 7 times
Summary
This study tested a two-step treatment for advanced colorectal cancer that hasn't responded to standard therapies. First, some patients received a chemotherapy drug (temozolomide) to make their cancer cells more genetically unstable. Then, they received an immunotherapy drug (pembrolizumab) to help their immune system attack the cancer. The goal was to see if this approach could shrink tumors in 107 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Grande Ospedale Metropolitano Niguarda
Milan, Italy
-
Istituto Clinico Humanitas
Rozzano, Italy
-
Istituto Europeo di Oncologia
Milan, Italy
-
Istituto Nazionale Tumori di Milano
Milan, Italy
Conditions
Explore the condition pages connected to this study.